Should I buy or sell Axsome Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks .

What is Axsome Therapeutics' stock price target for 2024?

12 Wall Street analysts have issued 12 month target prices for Axsome Therapeutics' shares. Their AXSM share price targets range from $81.00 to $190.00. On average, they predict the company's share price to reach $119.67 in the next year. This suggests a possible upside of 82.1% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts .

How have AXSM shares performed in 2024?

Axsome Therapeutics' stock was trading at $79.59 on January 1st, 2024. Since then, AXSM shares have decreased by 17.4% and is now trading at $65.72. View the best growth stocks for 2024 here .

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AXSM earnings forecast .

How can I listen to Axsome Therapeutics' earnings call?

Axsome Therapeutics will be holding an earnings conference call on Monday, May 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its earnings results on Tuesday, February, 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.21) by $0.48. The company earned $71.53 million during the quarter, compared to analysts' expectations of $70.38 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 70.67% and a negative net margin of 88.41%.

What ETFs hold Axsome Therapeutics' stock?

ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , ALPS Medical Breakthroughs ETF (SBIO) , Virtus LifeSci Biotech Products ETF (BBP) , iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC) . First Trust Nasdaq Pharmaceuticals ETF (FTXH) .

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Dicerna Pharmaceuticals (DRNA) , Amarin (AMRN) , Sarepta Therapeutics (SRPT) , Micron Technology (MU) , Pfizer (PFE) , AbbVie (ABBV) , Alibaba Group (BABA) and Bristol-Myers Squibb (BMY) .

When did Axsome Therapeutics IPO?

Axsome Therapeutics (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.15%), Yarbrough Capital LLC (0.01%) and Janiczek Wealth Management LLC (0.00%). Insiders that own company stock include Mark Coleman , Mark E Saad , Mark L Jacobson, Nick Pizzie and Roger Jeffs . View institutional ownership trends .

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AXSM Stock Alerts

$65.72

-3.99 (-5.72%)

(As of 04/18/2024 ET)

Compare

Today's Range: $65.61
▼
$70.08
50-Day Range: $68.21
▼
$97.64
52-Week Range: $55.02
▼
$98.40

Volume: 834,137 shs
Average Volume: 730,049 shs
Market Capitalization: $3.11 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $119.67

Get Axsome Therapeutics alerts:

Axsome Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.92 Rating Score
Upside/Downside: 82.1% Upside
$119.67 Price Target
Short Interest: Bearish
16.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.03
Upright™ Environmental Score
News Sentiment: -0.04
Based on 13 Articles This Week
Insider Trading: Selling Shares
$3.99 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.85) to $0.53 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.34 out of 5 stars

Medical Sector

114th out of 919 stocks

Pharmaceutical Preparations Industry

34th out of 405 stocks

4.5

Analyst's Opinion

Consensus Rating
Axsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Axsome Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
16.15% of the outstanding shares of Axsome Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Axsome Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Axsome Therapeutics has recently increased by 4.79%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Axsome Therapeutics does not currently pay a dividend.
Dividend Growth
Axsome Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Axsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.
Environmental Sustainability
The Environmental Impact score for Axsome Therapeutics is -1.03.

1.6

News and Social Media Coverage

News Sentiment
Axsome Therapeutics has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.
Search Interest
20 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.
MarketBeat Follows
Only 18 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,994,220.00 in company stock.
Percentage Held by Insiders
24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($3.85) to $0.53 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Axsome Therapeutics is -12.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Axsome Therapeutics is -12.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Axsome Therapeutics has a P/B Ratio of 16.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Axsome Therapeutics Stock (NASDAQ:AXSM)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AXSM Stock News Headlines

April 2, 2024 | insidertrades.com

Insider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells 24,662 Shares of Stock

April 18, 2024 | markets.businessinsider.com

Strong Buy on Axsome’s Auvelity Amidst Competitive MDD Market

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | markets.businessinsider.com

Auvelity’s Strong Performance Sustains Buy Rating for Axsome Therapeutics

April 15, 2024 | globenewswire.com

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

April 15, 2024 | americanbankingnews.com

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by Analysts

April 13, 2024 | americanbankingnews.com

Brokers Set Expectations for Axsome Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:AXSM)

April 12, 2024 | americanbankingnews.com

FY2026 EPS Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Cut by Analyst

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 11, 2024 | americanbankingnews.com

Axsome Therapeutics (NASDAQ:AXSM) Earns Overweight Rating from Cantor Fitzgerald

April 10, 2024 | fool.com

2 Under-the-Radar Growth Stocks to Consider

April 10, 2024 | globenewswire.com

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

April 2, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion Potential

April 2, 2024 | finance.yahoo.com

Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)

April 1, 2024 | globenewswire.com

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

March 27, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Axsome Therapeutics: Diverse Portfolio and Market Potential Despite Challenges

March 27, 2024 | investorplace.com

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

March 26, 2024 | markets.businessinsider.com

Maintaining Hold on Axsome Therapeutics: Weighing AXS-12’s Modest Efficacy Against Competitive and Market Risks

March 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)

March 25, 2024 | msn.com

What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?

March 25, 2024 | globenewswire.com

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

March 25, 2024 | reuters.com

Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial

March 25, 2024 | globenewswire.com

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

March 23, 2024 | finance.yahoo.com

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

March 23, 2024 | fool.com

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

March 22, 2024 | finance.yahoo.com

Axsome Triumphs Over Major Depressive Disorder With Auvelity

March 19, 2024 | msn.com

Baird starts Axsome at outperform, cites upcoming data

See More Headlines

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AXSM
CUSIP: N/A
CIK: 1579428
Web: axsome.com
Phone: (212) 332-3241
Fax: 212-320-0245
Employees: 545
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $119.67
High Stock Price Target: $190.00
Low Stock Price Target: $81.00
Potential Upside/Downside: +71.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.92
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-239,240,000.00
Net Margins: -88.41%
Pretax Margin: -88.06%
Return on Equity: -70.67%
Return on Assets: -27.47%

Debt

Debt-to-Equity Ratio: 0.93
Current Ratio: 3.63
Quick Ratio: 3.52

Sales & Book Value

Annual Sales: $270.60 million
Price / Sales: 12.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.04 per share
Price / Book: 17.25

Miscellaneous

Outstanding Shares: 47,370,000
Free Float: 35,767,000
Market Cap: $3.30 billion
Optionable: Optionable
Beta: 1.13

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Herriot Tabuteau M.D. (Age 56)
Founder, Chairman, CEO & President
Comp: $1.32M
Mr. Nick Pizzie CPA (Age 49)
M.B.A., Chief Financial Officer
Comp: $732.94k
Mr. Mark L. Jacobson (Age 41)
COO & Secretary
Comp: $784.66k
Mr. Hunter Murdock Esq. (Age 44)
General Counsel & Secretary
Comp: $735.39k
Dr. Amanda Jones Pharm.D. (Age 41)
Senior Vice President of Clinical Development
Ms. Lori Englebert M.B.A. (Age 46)
Executive Vice President of Commercial & Business Development
Joseph Debrah-Afful CPA
M.B.A., Director of Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.
What is Axsome Therapeutics' stock price target for 2024?: 12 Wall Street analysts have issued 12 month target prices for Axsome Therapeutics' shares. Their AXSM share price targets range from $81.00 to $190.00. On average, they predict the company's share price to reach $119.67 in the next year. This suggests a possible upside of 82.1% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.
How have AXSM shares performed in 2024?: Axsome Therapeutics' stock was trading at $79.59 on January 1st, 2024. Since then, AXSM shares have decreased by 17.4% and is now trading at $65.72.
View the best growth stocks for 2024 here.
When is Axsome Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AXSM earnings forecast.
How can I listen to Axsome Therapeutics' earnings call?: Axsome Therapeutics will be holding an earnings conference call on Monday, May 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Axsome Therapeutics' earnings last quarter?: Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its earnings results on Tuesday, February, 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.21) by $0.48. The company earned $71.53 million during the quarter, compared to analysts' expectations of $70.38 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 70.67% and a negative net margin of 88.41%.

What ETFs hold Axsome Therapeutics' stock?: ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH).
What other stocks do shareholders of Axsome Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).
When did Axsome Therapeutics IPO?: Axsome Therapeutics (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
Who are Axsome Therapeutics' major shareholders?: Axsome Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.15%), Yarbrough Capital LLC (0.01%) and Janiczek Wealth Management LLC (0.00%). Insiders that own company stock include Mark Coleman, Mark E Saad, Mark L Jacobson, Nick Pizzie and Roger Jeffs.
View institutional ownership trends.
How do I buy shares of Axsome Therapeutics?: Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXSM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Axsome Therapeutics (AXSM) Stock Price, News & Analysis

Axsome Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Axsome Therapeutics Stock (NASDAQ:AXSM)

AXSM Stock Price History

AXSM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AXSM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™